How certain proteins affect immune T cells in fighting tumors
Ubiquitin ligase regulation of tissue-resident T cell and anti-tumor activity
This study is looking at how certain immune cells, called CD8+ T cells, can become less effective at fighting tumors and aims to understand how a special type of these cells, known as tissue-resident memory T cells, can stay strong and help improve cancer treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10877814 on NIH RePORTER |
What this research studies
This research investigates how CD8+ T cells, which are crucial for recognizing and eliminating tumor cells, can lose their effectiveness in the presence of tumors. It focuses on understanding the role of tissue-resident memory T cells (TRM) in cancer, particularly how these cells can maintain their function and improve responses to immunotherapy. By comparing TRM from healthy tissues and exhausted T cells from tumors, the study aims to identify key genes that influence T cell function and survival in the tumor environment. This could lead to new strategies for enhancing anti-tumor immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who have CD8+ T cells present in their tumors and are undergoing or considering immunotherapy.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not involve CD8+ T cell activity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments for cancer patients by enhancing the effectiveness of their immune responses.
How similar studies have performed: Previous research has shown promising results in enhancing T cell function through similar approaches, indicating potential for success in this area.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Goldrath, Ananda W — University of California, San Diego
- Study coordinator: Goldrath, Ananda W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.